GLP-1 Receptor Agonists in Mood Disorders: A Psychiatric Perspective

Area of Science:

• Neuroscience
• Metabolic Psychiatry
• Pharmacology

Background:

• Mood disorders like MDD and BD are linked to metabolic dysfunction, particularly insulin resistance (IR).
• IR contributes to inflammation, HPA axis dysregulation, and impaired neuroplasticity, worsening mood symptoms.
• Psychotropic medications can exacerbate metabolic issues, creating a detrimental cycle.

Purpose of the Study:

• To explore the potential of GLP-1 RAs in addressing the metabolic-psychiatric interface in mood disorders.
• To review the central mechanisms of GLP-1 RAs relevant to mood regulation and neuroinflammation.
• To assess emerging clinical evidence for GLP-1 RAs in improving psychiatric and cognitive outcomes.

Main Methods:

• Review of preclinical studies on GLP-1 RAs' effects on neuroinflammation, neurogenesis, and behavior.
• Analysis of early clinical trials and observational data in patients with metabolic and psychiatric conditions.
• Identification of challenges and future research directions for GLP-1 RA application in mood disorders.

Main Results:

• GLP-1 RAs demonstrate anti-inflammatory, neurogenic, and reward pathway modulating effects in preclinical models.
• Early clinical data suggest GLP-1 RAs may improve depressive symptoms, cognition, and quality of life, independent of weight loss.
• Observational studies indicate reduced antidepressant use in populations treated with GLP-1 RAs.

Conclusions:

• GLP-1 RAs offer a promising therapeutic avenue for mood disorders, particularly in patients with metabolic burden.
• Further large-scale randomized controlled trials are necessary to establish efficacy and safety in primary psychiatric populations.
• Integrating GLP-1 RAs into multimodal care frameworks could bridge metabolic and psychiatric treatment.